AQP2 and Hyponatremia: In conclusion, urine aquaporin-2 is a novel predictor of responsiveness to tolvaptan, and the responders achieved amelioration of symptomatic congestion, normalization of hyponatremia, and improvement in renal function during tolvaptan treatment.